A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma

References

• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516–2522.
   PubMed Web of Science ®Google Scholar
• Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol. 2011;29(14):1827–1834.
   PubMed Web of Science ®Google Scholar
• Alonso-Álvarez S, Magnano L, Alcoceba M, et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol. 2017;178(5):699–708.
   PubMed Web of Science ®Google Scholar
• Federico M, Caballero Barrigón MD, Marcheselli L, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 2018;5(8):e359–e367.
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Cin Oncol. 2009;27(27):4555–4562.
   PubMed Web of Science ®Google Scholar
• Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111–1122.
   PubMed Web of Science ®Google Scholar
• Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science (80. 2010;327(5966):656–661.
   PubMed Web of Science ®Google Scholar
• Li ZM, Huang JJ, Xia Y, et al. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One. 2012;7(7):e41658
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Boschini C, Gritti G, et al. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. Am J Hematol. 2013;88(12):1062–1067.
   PubMed Web of Science ®Google Scholar
• Bento L, Díaz-López A, Barranco G; the Grupo Español de Linfomas y Trasplante Autólogo (GELTAMO), et al. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). Br J Haematol. 2020;188(6):888–897.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Tomita N, Itabashi M, et al. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol. 2014;92(3):204–210.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow K, Habermann TM, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2012;157(3):321–330.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow K, Colgan JP, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica. 2012;97(2):262–269.
   PubMed Web of Science ®Google Scholar
• Reddy JP, Hernandez M, Gunther JR, et al. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol. 2018;180(4):545–549.
   PubMed Web of Science ®Google Scholar
• Marcheselli L, Bari A, Anastasia A, et al. Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Br J Haematol. 2015;169(4):544–551.
   PubMed Web of Science ®Google Scholar
• Cox MC, Nofroni I, Ruco L, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma. 2008;49(9):1745–1751.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS; Lymphoma/Leukemia Molecular Profiling Project, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–2323.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: Mechanism of action. Semin Hematol. 2010;47(2):115–123.
   PubMed Web of Science ®Google Scholar
• De Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol. 2005;23(26):6358–6363.
   PubMed Web of Science ®Google Scholar
• Küppers R, Stevenson FK. Critical influences on the pathogenesis of follicular lymphoma. Blood. 2018;131(21):2297–2306.
   PubMed Web of Science ®Google Scholar
• Kumagai S, Tashima M, Fujikawa J, et al. Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. Int J Hematol. 2014;99(6):737–742.
   PubMed Web of Science ®Google Scholar
• Belotti A, Doni E, Bolis S, et al. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large b-cell lymphoma patients in the rituximab era. Clin Lymphoma, Myeloma Leuk. 2015;15(4):208–213.
   PubMed Web of Science ®Google Scholar
• Lee SF, Luque-Fernandez MA. Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study. BMJ Open. 2017;7(11):e017904.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Cin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16(3):1141–1154.
   Web of Science ®Google Scholar
• Bachy E, Seymour JF, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Cin Oncol. 2019;37(31):2815–2824.
   PubMed Web of Science ®Google Scholar
• Mozas P, Nadeu F, Rivas-Delgado A, et al. Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. Blood Cancer J. 2020;10(3):1–9.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang H, Xia ZJ, et al. Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma. Ann Hematol. 2015;94(10):1645–1654.
   PubMed Web of Science ®Google Scholar
• Yang G, Mills M, Kim Y, et al. Enhancement of the follicular lymphoma international prognostic index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation. Blood Cancer J. 2020;9(12):104
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma. 2012;53(4):575–580.
   PubMed Web of Science ®Google Scholar